Skip to main content
Equibles

T. Rowe Price Investment Management, Inc.

Position in AKTS — Aktis Oncology, Inc.

CIK 1897612 BALTIMORE, MD
Back to AKTS Full portfolio

Position in AKTS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$66,118,136
+$28,123,140 QoQ
Shares Held
2,051,447
-3.4% QoQ
Ownership
3.69%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#5
of 114 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in AKTS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

T. Rowe Price Investment Management, Inc. holds $12,305,680,119 across 52 Biotechnology names. AKTS ranks #31 (0.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ASND
Ascendis Pharma A/S
 6,754,846 $1,801,652,525
2 ALNY
Alnylam Pharmaceuticals, Inc.
 5,642,173 $1,698,463,338
3 CYTK
Cytokinetics Inc
 18,718,498 $1,594,628,844
4 KYMR
Kymera Therapeutics, Inc.
 6,257,261 $717,520,118
5 PCVX
Vaxcyte, Inc.
 12,207,450 $709,619,068
6 DYN
Dyne Therapeutics, Inc.
 30,912,287 $686,561,894
7 CGON
CG Oncology, Inc.
 6,616,899 $470,130,673
8 IMNM
Immunome Inc.
 19,676,883 $416,953,150

All Filings in AKTS

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $66,118,136 2,051,447
2026-03-31 $37,994,996 2,123,812